Travere Therapeutics carries one of the more bullish Street ratings in biotech, with data providers describing the TVTX analyst consensus as a "Strong Buy." Reviewing the most recent individual targets, the range spans roughly $62 (Stifel, a Hold) to $90 (J.P. Morgan), with Guggenheim at $89, Wells Fargo at $80, Evercore ISI at $78, Wedbush at $76, Bank of America at $71, Canaccord Genuity at $70, Piper Sandler at $68, and H.C. Wainwright at $67. The arithmetic mean of these verified targets works out to approximately $75, which is the central target used here.
The dispersion matters. Bullish analysts argue the FSGS approval materially expands Filspari's addressable market and validates proteinuria reduction as a regulatory endpoint, while more cautious voices note that the drug's profit trajectory and competitive positioning are still unproven. Recent revisions have generally moved higher, with firms such as Guggenheim and J.P. Morgan raising targets after the FSGS decision, but the wide $62-to-$90 band shows the outcome is far from settled.
Travere shares traded near $52 in mid-October 2026, with a market capitalization of roughly $4.9 billion and a 52-week range of about $22.59 to $68.73. Reaching $75 would require an advance of approximately 43% from the current price, a substantial move that would also take the stock above its 52-week high of roughly $68.73 and into new territory.
The company remains unprofitable on a GAAP (generally accepted accounting principles) basis, reporting trailing-twelve-month revenue near $591 million and a diluted EPS (earnings per share) of about -$0.74, so the path to the target rests primarily on revenue growth and improving profitability rather than multiple expansion on current earnings. Filspari, already approved for IgA nephropathy (IgAN), is the commercial engine, and the new FSGS label meaningfully broadens the eligible patient pool the company estimates at more than 100,000 people across both indications.
The single most important catalyst is the April 2026 full approval of Filspari for FSGS, making it the first and only FDA-approved medicine for the disease. The approval was supported by the Phase 3 DUPLEX study, which showed a statistically significant 46% proteinuria reduction versus 30% for irbesartan, with stronger results in the approved non-nephrotic-syndrome subgroup. Analysts such as Jefferies' Maury Raycroft have pointed to meaningful peak-sales potential, with estimates in the neighborhood of $961 million by 2033 for the FSGS indication alone.
Beyond the label expansion, supporting factors include continued Filspari sales momentum in IgAN, a growing body of published clinical data, and the possibility that proteinuria reduction becomes an increasingly accepted surrogate endpoint for regulatory and payer decisions. Travere also reported roughly $489 million in cash, providing runway to fund commercialization.
The principal risks are commercial and competitive. Filspari carries boxed warnings for liver toxicity and birth defects, which complicate prescribing and monitoring. Novartis is advancing atrasentan in FSGS, and the broader rare kidney disease field is attracting investment that could erode Travere's first-mover advantage. The company is not yet profitable, and if revenue growth disappoints or operating expenses rise faster than expected, the path to sustained profitability would lengthen.
A slower-than-expected launch in FSGS, payer access challenges, or disappointing quarterly results could also trigger valuation compression in a biotech name that has already risen sharply, with a roughly 87% one-year return and a roughly 37% year-to-date gain. Finally, the wide analyst target range reflects genuine uncertainty about the durability of the growth story.
From a market structure standpoint, the 52-week high near $68.73 represents the clearest resistance level before any move toward $75, since the stock would need to break through that prior peak and sustain the advance. On the downside, the $40-to-$43 area, which previously acted as a consolidation zone before the FSGS approval, is a notable support level, with the broader 52-week low near $22.59 marking the lower bound of the range. The $75 target sits above all recent trading levels, meaning it requires a breakout rather than a return to previously established prices.
Analyst price targets generally reflect a forward-looking research horizon, often around 12 months, though individual firms may differ, and the exact horizon is not always disclosed. The most important near-term item is Travere's next earnings report, expected around late October 2026, which will show whether Filspari's IgAN franchise and the early FSGS launch are tracking toward analyst revenue assumptions.
Investors should also monitor quarterly Filspari prescriptions and net sales, updates on FSGS payer coverage and formulary access, any additional regulatory or clinical data readouts, revisions to individual analyst targets, and competitive developments from Novartis and other rare kidney disease programs. Changes in the biotechnology sector's risk appetite and interest-rate expectations can also influence the stock independently of company fundamentals.
For traders tracking TVTX and similar names, Tickeron's AI Daily Buy/Sell Signals offer a way to stay current on shifting conditions. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening alone. As a supplement to fundamental research, the tool can help identify momentum shifts as a name approaches key technical levels.
The question of whether Travere Therapeutics can reach $75 ultimately hinges on execution rather than the regulatory catalyst that has already materialized. The central target, derived from the mean of verified analyst price targets ranging from roughly $62 to $90, implies a substantial move of about 43% from the mid-$52 price and would require a breakout above the 52-week high. The strongest supports are the first-in-class FSGS approval, an expanding addressable market, and generally bullish analyst revisions. The principal obstacles are an unprofitable income statement, boxed-warning safety considerations, and intensifying competition. The wide spread between the lowest and highest targets underscores that while the Street is broadly constructive, there is no consensus on the pace or magnitude of the stock's next leg. Investors should watch the upcoming earnings report and Filspari prescription trends as the clearest near-term indicators of whether that path is opening or narrowing.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TVTX has been loosely correlated with MGTX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if TVTX jumps, then MGTX could also see price increases.
| Ticker / NAME | Correlation To TVTX | 1D Price Change % | ||
|---|---|---|---|---|
| TVTX | 100% | -0.29% | ||
| MGTX - TVTX | 47% Loosely correlated | -0.91% | ||
| GERN - TVTX | 42% Loosely correlated | -2.59% | ||
| LGND - TVTX | 41% Loosely correlated | -2.21% | ||
| PTGX - TVTX | 38% Loosely correlated | +1.05% | ||
| VCYT - TVTX | 37% Loosely correlated | -0.39% | ||
More | ||||